
AbbVie files lawsuit against Amgen over Humira copy
pharmafile | August 8, 2016 | News story | Research and Development, Sales and Marketing | AbbVie, Amgen, FDA, Humira, rheumatoid arthritis
Abbvie has filed a patent infringement lawsuit against Amgen over the latter firm’s copy of its Humira (adalimumab) rheumatoid arthritis drug.
The company has asserted that Amgen’s proposed ABP 501 biosimilar would violate at least 10 of its patents and up to as many as 51 other patents, and is seeking a court order to prevent its sale.
In July, the US Food and Drug Administration (FDA) voiced its unanimous recommendation of the biosimilar after calling it ‘highly similar’ to the original Humira.
The active ingredient of ABP 501 is an anti-tumour necrosis factor-alpha (TNF-α) monoclonal antibody which has a similar amino acid sequence as Humira and can be used to treat a ranges of afflictions including rheumatoid and psioriatic arthritis, spondylitis, moderate to severe psoriasis and Crohn’s disease.
Matt Fellows
Related Content

MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance
Microbial Resource Management (MRM) Health has announced that its lead programme, MH002, has received Investigational …

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation
Complement Therapeutics has announced that CTx001, its gene therapy treatment for geographic atrophy (GA) secondary …

Johnson & Johnson submits robotic surgical system for De Novo classification
Johnson & Johnson has announced the submission of its Ottava Robotic Surgical System for De …






